Salarius Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frederick E. Pierce
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2450 Holcombe Boulevard Houston TX United States of America 77021
- IPO Date
- Jan 29, 2015
- CIK
- 0001615219
- Website
- salariuspharma.com
- Similar Companies
- Business
- Salarius Pharmaceuticals, Inc. has recently undergone a transformative strategic shift, completing a definitive merger with Decoy Therapeutics. The combined entity will now operate under the name Decoy Therapeutics, leveraging its proprietary IMP3ACT™ platform, which employs machine learning and artificial intelligence for the accelerated design and production of innovative peptide conjugate therapeutics. This expanded focus encompasses addressing critical unmet medical needs in both oncology and infectious diseases, particularly respiratory viruses. The company's pipeline integrates Salarius's former assets, including SP-3164, an oral small molecule protein degrader now being considered for incorporation into a peptide-based proteolysis-targeting chimera (PROTAC) drug candidate. Furthermore, the ongoing investigator-initiated Phase 1/2 clinical study of seclidemstat (SP-2577), a targeted protein inhibitor, in hematologic cancers such as myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) at MD Anderson Cancer Center, will continue to be supported as the company evaluates broader strategic alternatives for this program. Decoy Therapeutics has secured non-dilutive funding from various sources, including federal governments and the Bill & Melinda Gates Foundation, validating its platform technology. Salarius Pharmaceuticals, Inc. maintains its headquarters in Houston, Texas.
Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 20.9%
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Down 2.6% – Should You Sell?
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Comparing NRx Pharmaceuticals (NASDAQ:NRXP) & Salarius Pharmaceuticals (NASDAQ:SLRX)
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRX
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge